Inhibition of neo‐intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel‐coated scoring balloon catheter. Issue 7 (20th December 2013)

• Record Type: Journal Article
• Authors: Cremers, Bodo; Schmitmeier, Stephanie; Clever, Yvonne P.; Gershony, Gary; Speck, Ulrich; Scheller, Bruno
• Is Part Of: Catheterization and cardiovascular interventions. Volume 84:Issue 7(2014:Dec. 01)
• Page Start: 1089
• Page End: 1098
• Publication Date: 2013-12-20
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25296
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <underline>Objective:</underline> Scoring balloons are particularly useful in the acute treatment of fibro‐calcific, bifurcation and in‐stent restenosis lesions but have not been shown to affect the restenosis rate. Conventional balloons coated with paclitaxel have recently been shown to reduce restenosis rates in certain lesion subsets, but are associated with suboptimal acute results. A novel paclitaxel‐coated scoring balloon was developed to overcome these limitations. <bold><underline>Design:</underline></bold> AngioSculpt<sup>®</sup> scoring balloons (SB) were coated with paclitaxel admixed with a specific excipient. <bold><underline>Setting and Interventions:</underline></bold> Four <italic>in vitro</italic> and <italic>in vivo</italic> studies were performed: (a) loss of the drug during passage to the lesion, (b) transfer of the drug to the vessel wall; (c) inhibition of neo‐intimal proliferation in porcine coronary arteries as compared to uncoated SB and the Paccocath™, and (d) evaluation of the dose‐response to 1.5–12 μg of paclitaxel/mm<sup>2</sup>. <bold><underline>Main outcome measures and Results:</underline></bold> Drug loss during delivery to the lesion was 17% ± 8%, and transfer to the vessel wall was 9% ± 4% of dose on unused balloons. The paclitaxel‐coated SB resulted in a lower late lumen loss of 0.27 ± 0.24 mm compared to 1.4 ± 0.7 mm with the uncoated SB (<italic>P</italic> = 0.001). Histomorphometry revealed larger luminal areas of 6.8 ± 1.6 mm<sup>2</sup> (paclitaxel‐coated SB) and 5.8 ± 1.7 mm<sup>2</sup> (Paccocath) as compared to the uncoated SB (2.3 ± 1.5 mm<sup>2</sup>; <italic>P</italic> = 0.001). No coating related adverse effects were observed on follow‐up angiography or histologic examination at the treatment site or downstream myocardium. <bold><underline>Conclusion:</underline></bold> A novel paclitaxel‐coated SB leads to a significant inhibition of neointimal proliferation in the porcine coronary model. © 2013 Wiley Periodicals, Inc.</p> </abstract>